Abstract
BackgroundSuccessful gene therapy will require targeted delivery vectors capable of self-directed localization. In this regard, the use of antibodies or single chain antibody fragments (scFv) in conjunction with adenovirus (Ad) vectors remains an attractive means to achieve cell-specific targeting. However, a longstanding barrier to the development of Ad vectors with genetically incorporated scFvs has been the biosynthetic incompatibility between Ad capsid proteins and antibody-derived species. Specifically, scFv require posttranslational modifications not available to Ad capsid proteins due to their cytoplasmic routing during protein synthesis and virion assembly.Methodology/Principal FindingsWe have therefore sought to develop scFv-targeted Ad vectors using a secreted scFv that undergoes the requisite posttranslational modifications and is trafficked for secretion. Formation of the scFv-targeted Ad vector is achieved via highly specific association of the Ad virion and a targeting scFv employing synthetic leucine zipper-like dimerization domains (zippers) that have been optimized for structural compatibility with the Ad capsid and for association with the secreted scFv. Our results show that zipper-containing Ad fiber molecules trimerize and incorporate into mature virions and that zippers can be genetically fused to scFv without ablating target recognition. Most importantly, we show that zipper-tagged virions and scFv provide target-specific gene transfer.Conclusions/SignificanceThis work describes a new approach to produce targeted Ad vectors using a secreted scFv molecule, thereby avoiding the problem of structural and biosynthetic incompatibility between Ad and a complex targeting ligand. This approach may facilitate Ad targeting using a wide variety of targeting ligands directed towards a variety of cellular receptors.
Highlights
Successful gene therapy will require both rational vector development and exploitation of disease-specific cellular physiology to design targeted gene delivery vectors
Vectors based on human adenovirus (Ad) serotypes 2 and 5 of species C continue to show increasing promise as gene delivery vehicles due to several key attributes: Ad vectors display in vivo stability and excellent gene transfer efficiency to numerous dividing and non-dividing cell targets, do not integrate into the host genome, and are rarely linked to any severe disease in immunocompetent humans
We have developed a system that maintains the divergent biosynthetic pathways of the antibody and adenovirus components via use of a secreted scFv molecule encoded by the vector
Summary
Successful gene therapy will require both rational vector development and exploitation of disease-specific cellular physiology to design targeted gene delivery vectors. Antibodies and recombinant antibody binding domains are potentially useful agents to achieve cell-specific targeting, due to their unparalleled affinity and specificity of binding to a wide range of target cell surface markers. On this basis, the development of Ad vectors with genetically incorporated antibody-derived moieties has been a long-standing goal. Successful gene therapy will require targeted delivery vectors capable of self-directed localization In this regard, the use of antibodies or single chain antibody fragments (scFv) in conjunction with adenovirus (Ad) vectors remains an attractive means to achieve cell-specific targeting. ScFv require posttranslational modifications not available to Ad capsid proteins due to their cytoplasmic routing during protein synthesis and virion assembly
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.